https://scholars.lib.ntu.edu.tw/handle/123456789/575659
標題: | Plasma Aldosterone Concentration as a Determinant for Statin Use among Middle-Aged Hypertensive Patients for Atherosclerotic Cardiovascular Disease | 作者: | JUI-HSIANG LIN YU-FENG LIN Wang, Wei-Jie SHIH-CHIEH CHUEH VIN-CENT WU Chu, Tzong-Shinn KWAN-DUN WU Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group |
關鍵字: | ASCVD; atherosclerotic cardiovascular disease; essential hypertension; plasma aldosterone concentration; primary hyperaldosteronism; statin;ASCVD; Atherosclerotic cardiovascular disease; Essential hypertension; Plasma aldosterone concentration; Primary hyperaldosteronism; Statin | 公開日期: | 24-十月-2018 | 卷: | 7 | 期: | 11 | 來源出版物: | Journal of clinical medicine | 摘要: | The use of statin therapy on the prevention of atherosclerotic cardiovascular disease (ASCVD) is recommended by the American College of Cardiology (ACC) and the American Heart Association (AHA); nevertheless, its validation on primary aldosteronism (PA) patients has not been reported. We investigated the risk of incident ASCVD in middle-aged patients with PA compared with essential hypertension (EH) based on ACC/AHA recommendations. We enrolled 461 PA patients and 553 EH patients. Even though the ratio of metabolic syndrome in each group was similar, the PA group had higher systolic blood pressures, higher low-density lipoprotein levels, higher plasma aldosterone concentration (PAC), lower high-density lipoprotein levels, and higher 10-year ASCVD compared to the EH group. The discriminative power for predicting ASCVD by the recommended statin use from the ACC/AHA guidelines was proper in the PA group (i.e., under the receiver operating characteristic curve (95% confidence interval; 0.94 (0.91⁻0.96)). The generalized additive model showed patients with PAC higher than 60 ng/dL accompanying the standard timing of the statin use suggested by the ACC/AHA. The ACC/AHA guidelines have good discriminative power in the prediction of middle-aged high-risk hypertensive patients, while PAC identifies those high-risk individuals who may benefit from early statin therapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/575659 | ISSN: | 2077-0383 | DOI: | 10.3390/jcm7110382 | SDG/關鍵字: | aldosterone; high density lipoprotein; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein; low density lipoprotein cholesterol; potassium; renin; triacylglycerol; adrenal hyperplasia; adult; aged; Article; concentration (parameters); coronary artery atherosclerosis; estimated glomerular filtration rate; female; glucose blood level; human; hypertension; hypertensive patient; major clinical study; male; metabolic syndrome X; primary hyperaldosteronism; receiver operating characteristic; systolic blood pressure |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。